Skip to main content

Foghorn Therapeutics Inc.

FHTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001822462

No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 121 institutions reported holding it in 13F filings for Q3 2026, worth $168.2M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$103.1M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +20 vs. previous quarter
121
13F valueReported value at the end of Q3 2026
$168.2M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$30.9M
+36.8% year over year
Net income, FY2025
-$74.3M
No comparable prior period
Free cash flow, FY2025
-$86.1M
No comparable prior period
Revenue, Q3 FY2026
$83.5M
+924.7% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $74.3M (240.3% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
2.25M
Shares sold short
Change
−203.2K
−8.3% vs. previous
Days to cover
3.90
At average daily volume

Superinvestors holding FHTX, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding FHTX at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Foghorn Therapeutics Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 24, 2024 (view filing)Sep 20-234 daysCosta CarlosChief People OfficerSSale−36.6K$10.04−$367.7K−100.0%0 after2 lots10b5-1
Sep 20, 2024 (view filing)Sep 182 daysCosta CarlosChief People OfficerSSale−11.6K$10.05−$116.3K−100.0%0 after10b5-1
Sep 18, 2024 (view filing)Sep 16-172 daysCosta CarlosChief People OfficerSSale−10.7K$10.04−$107.1K−100.0%0 after2 lots10b5-1
Sep 11, 2024 (view filing)Sep 92 daysBellon Steven F.Chief Scientific OfficerSSale−20.0K$9.50−$190.0K−16.4%102.0K after10b5-1
May 24, 2024 (view filing)5:05 PM ETMay 222 daysAfeyan Noubar and 3 others10% OwnerPPurchase+3.63M$5.51+$20.0M–1.81M afterDerivative2 lots
Mar 12, 2024 (view filing)Mar 111 dayCavalie FannyChief Strategy/Bus Ops OfficerSSale−11.0K$6.56−$72.2K−12.6%76.0K after
Aug 18, 2023 (view filing)Aug 162 daysAgresta SamuelChief Medical OfficerSSale−311.3K$8.25−$2.57M−100.0%0 after

Top 10 13F holders, Q3 2026

See all 121 holders

The largest institutional positions in Foghorn Therapeutics Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding FHTX in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Flagship Pioneering Inc.12,674,120$45.2M2.31%00.0%Unchanged
BVF Inc5,842,000$20.9M0.69%00.0%Unchanged
FMR LLC5,546,349$19.8M0.00%−159,609−2.8%Reduced
Deerfield Management Company, L.P. (Series C)4,394,367$15.7M0.24%00.0%Unchanged
BlackRock, Inc.3,065,236$10.9M0.00%+438,404+16.7%Added
Raymond James Financial Inc2,479,621$8.85M0.00%−10,357−0.4%Reduced
Vanguard Capital Management LLC1,586,219$5.66M0.00%+91,608+6.1%Added
Euclidean Capital LLC1,573,761$5.62M1.74%00.0%Unchanged
Geode Capital Management, LLC861,655$3.08M0.00%−49,211−5.4%Reduced
Siren, L.L.C.720,720$2.57M0.06%00.0%Unchanged

Holders of 5% or more of FHTX

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Foghorn Therapeutics Inc..

Largest holders of FHTX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Flagship Ventures Fund V, L.P.13D/A27.20%20.8M shares–May 24, 20242 filingsJan 13, 2026SEC
Biotechnology Value Fund L P13G/A14.30%8.51M shares+4.31 ppfrom 9.99%May 30, 20243 filingsOct 5, 2026SEC
FMR LLC13G/A11.60%6.79M shares+1.40 ppfrom 10.20%Feb 8, 20217 filingsMay 6, 2026SEC
Flynn James E13G/A8.64%5.14M shares–Sep 20, 20242 filingsMay 14, 2026SEC